Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-12-018123
Filing Date
2012-03-29
Accepted
2012-03-29 17:02:18
Documents
16
Period of Report
2011-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F v307471_20f.htm 20-F 2390344
2 EXHIBIT 21.1 v307471_ex21-1.htm EX-21.1 2723
3 EXHIBIT 23.1 v307471_ex23-1.htm EX-23.1 2539
4 EXHIBIT 23.2 v307471_ex23-2.htm EX-23.2 2279
5 EXHIBIT 31.1 v307471_ex31-1.htm EX-31.1 7496
6 EXHIBIT 31.2 v307471_ex31-2.htm EX-31.2 7345
7 EXHIBIT 32.1 v307471_ex32-1.htm EX-32.1 4766
8 GRAPHIC footer.jpg GRAPHIC 5639
9 GRAPHIC header.jpg GRAPHIC 4082
10 GRAPHIC logo.jpg GRAPHIC 4139
11 GRAPHIC pg14.jpg GRAPHIC 14408
12 GRAPHIC pg18a.jpg GRAPHIC 26990
13 GRAPHIC pg18b.jpg GRAPHIC 25624
14 GRAPHIC pg40a.jpg GRAPHIC 25357
15 GRAPHIC pg40b.jpg GRAPHIC 26800
16 GRAPHIC pg9.jpg GRAPHIC 10778
  Complete submission text file 0001144204-12-018123.txt   2617865
Mailing Address 85 MEDINAT HAYEHUDIM ST. PITUACH, PO BOX 4033 HERZLIYA L3 46140
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

EIN.: 000000000
Type: 20-F | Act: 34 | File No.: 000-51310 | Film No.: 12724756
SIC: 2834 Pharmaceutical Preparations